Dermatological reparative means and its external use for skin care, prevention and treatment of skin lesions of various etiology

FIELD: medicine.

SUBSTANCE: invention is a dermatological reparative means containing zoosterol, lightly crosslinked acrylic polymers, representing acrylic acid homopolymer esters, cross-stitched by allyl saccharose, allyl pentaerythritol or divinyl glycol, preservatives, caustic soda and distilled water, at that, components are at a specific ratio in wt %.

EFFECT: increased effectiveness of action due to high adhesion to the skin surface, increased duration of agent action, shortened duration of the healing process, enhanced regeneration of the affected skin, lack of toxicity, and suppression of external allergic reactions.

4 cl, 3 tbl

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents an agent for preventing or reducing pigmentation, containing a compound presented by the following formula (1) its stereoisomer and/or its pharmacologically acceptable salt, wherein: R1 represents a hydrogen atom or an alkyl group with a linear or branched chain having 1-4 carbon atoms; R2 represents a hydrogen atom or an unsubstituted aliphatic hydrocarbon group having 1-4 carbon atoms; R3 represents an unsubstituted aromatic group having 5-15 carbon atoms, substituted by an alkyl group having 1-6 carbon atoms, by an alkoxy group containing an alkyl chain having 1-6 carbon atoms, or by a phenyl group; R3 also represents an aromatic group having 5-15 carbon atoms; n is equal to 1 or 2, and m represents an integer falling within 0 to 3.

EFFECT: preparing the agent for preventing or reducing pigmentation.

10 cl, 10 ex, 6 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new idebenone derivatives substituted by carboxylic acid with general formula I wherein R1 represents C2-C22 saccharic acid with a direct or branched chain, while two or more hydroxy groups are independently substituted by C1-C22 carboxylic acid, wherein the term 'branched' refers to one or more groups of a lower alkyl. The invention also refers to a formulation for skin treatment containing the above idebenone derivatives, a method of treating the skin changes by local applications with these idebenone derivatives, as well as to methods of synthesis thereof. When adding the idebenone derivatives according to the present invention into the formulations for local application, they possess the antioxidant action effective in treating the skin changes.

EFFECT: above idebenone derivatives have unexpectedly occurred to be effective in skin treatment, especially in relation to skin tolerance.

20 cl, 1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents composition for reducing injury caused by ultraviolet radiation, which includes one or more compounds selected from the group consisting of D-methionine and its salts.

EFFECT: invention provides creation of stable and safe composition, which can be applied daily.

10 cl, 37 ex, 7 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of cosmetology. Described is a stable and safe antioxidant composition, which can be applied daily. In particular, described is the antioxidant composition, which contains one or more compounds, selected from the group, which consists of D-aspartic acid, its derivatives and/or its salts. The composition can be applied with the purpose of suppressing and/or relief of a skin condition. Conditions of skin can include, but are not limited by them, small wrinkles, rough skin, dry skin, skin cancer, skin allergy, skin inflammation, and light-sensitive dermatosis. The composition can be applied as a medication for the external application on the skin.

EFFECT: invention ensures an increase of the antioxidant effect of the composition.

4 cl, 5 dwg, 31 ex

FIELD: medicine.

SUBSTANCE: topical cosmetic composition effective for stimulating each of SIRT1, Gadd45b and SOD2, which contains a senna alata leaves extract, a great morinda leaves extract and a melon flesh extract taken in certain proportions. A method for the protection against or recovery of an oxidative injury involving administering the topical composition containing the senna alata leaves extract, the great morinda leaves extract and the melon flesh extract taken in certain proportions. The topical cosmetic or dermatological composition for stimulating each of SIRT1, Gadd45b and SOD2. Using the above composition for producing a drug preparation for treating the oxidative injury.

EFFECT: composition is effective for stimulating each of SIRT1, Gadd45b and SOD2.

8 cl, 1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical and cosmetic industries and represents a composition for relieving an ultraviolet injury by post-irradiation administration of a composition containing one or more compounds specified in a group consisting of D-glutamic acid and/or its salts, and at least one acceptable additive.

EFFECT: invention provides effective relief of the ultraviolet skin injuries.

11 cl, 34 ex, 1 tbl, 8 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and presents application of zeaxanthin per se or in combination with rutin or with spremidin, or as with rutin, and with spremidin, for treatment of irritability of hairy part of head skin, including chemical therapy-induced alopecia, androgenic alopecia and telogene with hair loss.

EFFECT: invention ensures extension of arsenal of means for treating disorders of hairy part of head skin.

20 cl, 23 ex, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical composition in the form of a skin protection paste. The composition contains a film-forming agent representing poly(butyl methacrylate-co-methyl methacrylate), hydrocolloid, a filling agent, a softening agent and an alcoholic diluent in the certain proportions.

EFFECT: pharmaceutical composition has a prolonged shelf life and is able to ensure a uniform skin coverage which is characterised by the balanced characteristics of durability and flexibility.

3 cl, 2 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for reducing oxidative stress in the skin caused by sunlight or ultraviolet light. A chewable composition for reducing oxidative stress caused by sunlight or ultraviolet light (UVB) in the skin, containing vitamin C, vitamin E, green tea extract having the content of epigallocatechin (EGC) of at least 20%, and gallic acid in a certain amount. A method for preserving an individual's healthy skin in the oxidative process caused by sunlight or ultraviolet light involving the oral administration of the composition.

EFFECT: composition is effective for reducing oxidative stress in the skin caused by sunlight or ultraviolet light.

14 cl, 6 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatocosmetology, and can be used in treatment of dehydrated involutionally changed face skin in women. For this purpose the first stage successive complex morphofunctional examination of state of moisture-holding structures of epidermal and dermal face skin layers with estimation of their dehydration degree is carried out. First, epidermal layer is examined. If indices of corneal layer moisture degree are lower than 30 conv.units CM, those of moisture-holding function of epidermis are higher than 13 gram/hour/m2, degree of relief is higher than 25 conv.units, wrinkling is higher than 20 conv.units, porosity is 23 conv.units, as well as presence of roughness and thinning of epidermis contours, reduction of its echogenesity, smoothing of boundary between epidermis and derma with absence of changes in dermal structures, structural and functional disorders of epidermis with expressed dehydration are diagnosed. After that, state of moisture-holding structures of dermal skin layer is analysed. Degree of its elasticity, presence or absence of homogeneity, thickness and state of dermoepidermal connection are determined. In case of value of dermal structure elasticity indexes lower than 50%, reduction of derma thickness below index value 1.670.381, detection of non-homogeneity of dermal structures, development of hypoechogenic zones, structural and functional disorders of derma with expressed dehydration are diagnosed. Then, correction of dehydrated involutionally changed skin is carried out. In case if structural and functional disorders of epidermis are present, preparation "Hyalrepair-07M/mesolift" with concentration of hyaluronic acid 2 mg/ml is introduced intradermally in dose 1 ml on face area 1 time per week, the course includes 5 procedures. In case if structural and functional disorders of derma and epidermis are present, preparation "Hyalrepair-02 bioreparant" with concentration of hyaluronic acid 14 mg/ml is introduced in dose 1 ml on face area 1 time per 3 weeks, the course includes 3 procedures.

EFFECT: method ensures obtaining stable and expressed therapeutic effect in case of introduction of hyaluronic acid preparations due to identification and taking into account determined parameters.

1 tbl, 2 ex

Crystals // 2556206

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes crystals of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulphonyl)acetamide ("compound A"), as a form I of the compound A crystal, which shows diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in its power X-ray diffraction spectrum, as a form II of the compound A crystal, which shows diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in its power X-ray diffraction spectrum, as a form III of the compound A crystal, which shows diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in its power X-ray diffraction spectrum. There are also described methods for producing the forms I, II and III of the compound A crystal, based pharmaceutical composition and PGI2 receptor agonist agent, an accelerating agent for angiogenic therapy, gene engineering or autoimmune bone marrow transplantation, and an accelerating agent for angiogenesis for peripheral artery recovery or angiogenic therapy on the basis thereof; there are also described a preventive or therapeutic agent for a wide range of diseases and conditions.

EFFECT: preparing the new therapeutic agent for the wide range of diseases and conditions.

11 cl, 6 dwg, 6 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention concerns using synthetic peptide of general formula H2N-L-Glu-L-Trp-D-Ala-COOH as a wound healing agent possessing the immunostimulatory effect.

EFFECT: creating the new synthetic wound healing agent having high biological activity.

2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: wound is preliminary treated with antiseptics. Then the preparation is injected drug directly under the base of the lesion. The preparation is used as the extract from the reindeer velvet antlers at a dose of 5-10 ml per one wound three times, once every 5 days.

EFFECT: use of the preparation Pantoin, the extract of reindeer velvet antlers, enables to speed up significantly the healing process of tear-contused wounds in horses and facilitates significantly the process of wound healing, particularly in the pasture period of maintenance.

2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: ointment contains wax 13-15 wt %, glycerol 15-20 % and vegetable oil; the prepared ointment mass is exposed to ozone for 15-20 min in a yield amount of 10 mg/l.

EFFECT: invention provides the advanced healing efficacy with no side effects by reducing the time of wound cleansing from purulo-necrotic tissues.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to combustiology, and can be applied in process of treating burn wounds of III a and III b degree. For this purpose applied are cultured dermal allofibroblasts on 5-8 passage with concentration 250000 cells/ml as part of composition, which includes as carrier hydroxyethylcellulose natrosol and native collagen. After uniform distribution of medication on wound surface relief fixing with inert mesh covering "Lomatul-N" is carried out.

EFFECT: invention makes it possible to achieve fast recovery skin, reduction of probability of burn disease complications, improvement of functional and cosmetic results of treatment.

1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: burn-treating composition for local application based on Vaseline lanolin, or carbopol, or hydrogel; as an active substance, the composition contains 5% dry extract of the herbal raw material big-flowered self and self-heal containing 60% rosmarinic acid.

EFFECT: above composition is effective for treating burns; it is non-toxic.

7 tbl, 10 ex, 12 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to physiotherapy, dermatology and cosmetology, and can be used in stimulating regenerative processes in the face and/or neck skin. That is ensured by performing three stages, first two of which involve preparing to the third one. The first stage involves blood sampling from the patient, recovering the blood plasma, and enriching it with thrombocytes; the purified and enriched plasma is administered intradermally under the skin. Two days later, the second stage follows that involves the subcutaneous injections of hyaluronic acid. The third stage is performed 2-3 days later to expose different skin layers to laser light passing through different face and/or neck sections two to five times for one procedure. Passing once involves the alternating short-wave and long-wave laser exposure at a wave length of 1564-2940 nm. The procedure is repeated every 3-5 days with an increasing laser beam pulse energy from 35 mJ to 65 mJ.

EFFECT: method provides the safe effective stimulation of the regenerative processes in the face and/or neck skin ensured by the complex exposure covering different layers of derma and epidermis and involving different regeneration links.

2 ex

FIELD: medicine.

SUBSTANCE: invention represents an agent for treating septic wounds, pus pockets and trophic ulcers containing betaine hydrochloride, methyluracil, trimecaine, pepsin powder and polyethylene oxide 400 with the ingredients taken in certain proportions, wt %, and polyethylene oxide 400 is taken in an amount of 87.0-84.0 ml.

EFFECT: invention provides fastening necrolysis, intensifies bactericidal action, stimulates regeneration, prevents secondary infection.

4 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to the field of veterinary and is intended for fighting porcine reproductive and respiratory syndrome (PRRS). The method includes the vaccination of pigs with PRRS with the provision of a reduction of hyperthermia duration and protection of lung integrity. The vaccine is obtained by a method, including mixing a live vaccine, prepared for immediate introduction, with an adjuvant-diluent (AD). The said adjuvant-diluent represents an "oil-in water" type emulsion, which contains per 100% of its weight: from 99 to 50 wt % of water and from 1 to 50 wt % of an oil adjuvant. The oil adjuvant contains per 100 % of its weight: from 1 to 95 wt % of at least one mineral oil and from 1 to 80 wt % of at least one SAS. The mineral oil represents oil of a Marcol or Draekol type. SAS represents an ester, obtained by the condensation of a fatty acid with sorbitol or mannitol.

EFFECT: obtaining the preparation for fighting reproductive and respiratory syndrome.

7 cl, 9 tbl, 1 ex

Up!